Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.45 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822035 | 0.85 | ALDH1A1 (0.49) | ALDH1A1MAPTGAAL3MBTL1KMT2A | |
| SCHEMBL20796167 | 0.84 | ADAM17 (0.70) | LMNATSHRALDH1A1ADAM17PKM | |
| SCHEMBL12252783 | 0.82 | LMNA (0.52) | LMNATSHRALDH1A1ADAM17MAPT | |
| SCHEMBL25773657 | 0.82 | ADAM17 (0.70) | ALDH1A1ADAM17MAPTHPGDTDP1 | |
| SCHEMBL13754336 | 0.80 | ALOX5 (0.54) | LMNATSHRALDH1A1ADAM17PKM | |
| SCHEMBL13884938 | 0.79 | ALDH1A1 (0.62) | TSHRALDH1A1MAPTHPGDPKM | |
| SCHEMBL13709052 | 0.79 | L3MBTL1 (0.56) | ALDH1A1MAPTGAAALOX5MT-CO2 | |
| SCHEMBL10082605 | 0.79 | ALDH1A1 (0.60) | LMNATSHRALDH1A1MAPTTDP1 | |
| SCHEMBL8312798 | 0.76 | MEN1 (0.52) | LMNATSHRALDH1A1GAAPOLB | |
| SCHEMBL3485977 | 0.76 | ALDH1A1 (0.58) | LMNAALDH1A1MAPTTDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105205-A1 | ANTIBODY-DRUG CONJUGATES (A2DCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| WO-2023097249-A2 | COMPOSITIONS AND METHODS FOR DNA BINDING AND TRANSCRIPTIONAL REGULATION | THE UNIVERSITY OF CHICAGO (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma AG (DE) | 2018-07-05 | — | — | US | disclosed |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | US | disclosed |
| EP-2686019-B1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS | PASTEUR INSTITUT (FR) | 2017-03-01 | — | — | EP | disclosed |
| US-20160354483-A1 | COMPOUNDS, CONJUGATES AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-12-08 | — | — | US | disclosed |
| EP-2249873-B1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS | PASTEUR INSTITUT (FR) | 2016-11-16 | — | — | EP | disclosed |
| US-9353150-B2 | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140187500-A1 | COMPOUNDS, CONJUGATES AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2505210-A1 | Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanionic polypeptide for the treatment of aids | INSTITUT PASTEUR (FR) | 2012-10-03 | — | — | EP | disclosed |
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | SEAGEN INC. | 2009-02-12 | — | — | US | disclosed |
| US-7232805-B2 | Cobalamin conjugates for anti-tumor therapy | INFLABLOC PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232805-B2 | Cobalamin conjugates for anti-tumor therapy | INFLABLOC PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | LMNA 552/4885TSHR 4701/4885ALDH1A1 1427/4885 |
| US-20140187500-A1 | COMPOUNDS, CONJUGATES AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES | DNPEP, NPEPPS, PIN1 | LMNA 3893/4885TSHR 1676/4885ALDH1A1 3277/4885 |
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | CTSL, DNPEP, CTSE | LMNA 1891/4885TSHR 2750/4885ALDH1A1 2008/4885 |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | LMNA 4388/4885TSHR 3868/4885ALDH1A1 1644/4885 |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | TNFSF11, TNFRSF9, CD40 | LMNA 4099/4885TSHR 2038/4885ALDH1A1 2346/4885 |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | LMNA 2730/4885TSHR 4525/4885ALDH1A1 499/4885 |
| US-20160354483-A1 | COMPOUNDS, CONJUGATES AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES | DNPEP, NPEPPS, PIN1 | LMNA 3893/4885TSHR 1676/4885ALDH1A1 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.